Tokyo Tape
Sign in
← Falco Holdings

Quarterly report · Q2

4671.TEDINET S100S7JG
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥21.3bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥46.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥24.2bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥851m2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥1.7bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥931m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥3.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.9bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥1.1bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥1.9bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥629m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥629m2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥1.1bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥36.7bnat 2023-09-30Cons.Assets
Total assets¥38.9bnat 2023-03-31Cons.Assets
Total assets¥38.7bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥10.7bnat 2023-09-30Cons.Liabilities
Total liabilities¥12.3bnat 2023-03-31Cons.Liabilities
Net assets / equity¥26.0bnat 2023-09-30Cons.Net assets
Net assets / equity¥26.6bnat 2023-03-31Cons.Net assets
Net assets / equity¥24.3bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥9.2bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥12.6bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥9.2bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥12.6bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥10.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.6bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥2.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥322m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥249m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥448m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥937m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥56.292023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥45.342023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥215.292022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥107.52022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥65.162022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥56.142023-04-01 → 2023-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥214.032022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥107.182022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio70.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio68.2%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30¥0
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30¥0
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥270m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥0
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥689m
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥385m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥449m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥449m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥46m
—segment totalrevenue2023-04-01 → 2023-09-30¥21.3bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥21.3bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥0
—segment totalsegment profit2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥4m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥4m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥213m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥15.9bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥15.9bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥4m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.7bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥320m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥293m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥293m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥99m
—segment totalrevenue2022-04-01 → 2022-09-30¥24.2bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥24.2bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥4m
—segment totalsegment profit2022-04-01 → 2022-09-30¥2.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 539
ItemContextValueUnit
Operating incomePrior1YTDDuration1741000000JPY
Operating incomeCurrentYTDDuration851000000JPY
Dividends income noiPrior1YTDDuration73000000JPY
Dividends income noiCurrentYTDDuration55000000JPY
Reversal of allowance for doubtful accounts noiPrior1YTDDuration0JPY
Reversal of allowance for doubtful accounts noiCurrentYTDDuration1000000JPY
Subsidy income noiPrior1YTDDuration35000000JPY
Subsidy income noiCurrentYTDDuration1000000JPY
Other noiPrior1YTDDuration43000000JPY
Other noiCurrentYTDDuration53000000JPY
Non operating incomePrior1YTDDuration152000000JPY
Non operating incomeCurrentYTDDuration110000000JPY
Interest expenses noePrior1YTDDuration10000000JPY
Interest expenses noeCurrentYTDDuration5000000JPY
Commission fee noePrior1YTDDuration2000000JPY
Commission fee noeCurrentYTDDuration2000000JPY
Loss on insurance cancellation noePrior1YTDDuration0JPY
Loss on insurance cancellation noeCurrentYTDDuration11000000JPY
Loss on operation of investment noePrior1YTDDuration0JPY
Loss on operation of investment noeCurrentYTDDuration6000000JPY
Other noePrior1YTDDuration2000000JPY
Other noeCurrentYTDDuration5000000JPY
Non operating expensesPrior1YTDDuration16000000JPY
Non operating expensesCurrentYTDDuration30000000JPY
Ordinary incomePrior1YTDDuration1877000000JPY
Ordinary incomeCurrentYTDDuration931000000JPY
Gain on sales of investment securities eiPrior1YTDDuration69000000JPY
Gain on sales of investment securities eiCurrentYTDDuration68000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration－JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration1000000JPY
Gain on reversal of asset retirement obligations eiPrior1YTDDuration－JPY
Gain on reversal of asset retirement obligations eiCurrentYTDDuration68000000JPY
Extraordinary incomePrior1YTDDuration69000000JPY
Extraordinary incomeCurrentYTDDuration138000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration3000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration11000000JPY
Loss on valuation of investment securities elPrior1YTDDuration18000000JPY
Loss on valuation of investment securities elCurrentYTDDuration－JPY
Impairment loss elPrior1YTDDuration0JPY
Impairment loss elCurrentYTDDuration0JPY
Office transfer expenses elPrior1YTDDuration－JPY
Office transfer expenses elCurrentYTDDuration7000000JPY
Extraordinary lossPrior1YTDDuration22000000JPY
Extraordinary lossCurrentYTDDuration18000000JPY
Income before income taxesPrior1YTDDuration1924000000JPY
Income before income taxesCurrentYTDDuration1050000000JPY
Income taxes currentPrior1YTDDuration723000000JPY
Income taxes currentCurrentYTDDuration412000000JPY
Income taxes deferredPrior1YTDDuration74000000JPY
Income taxes deferredCurrentYTDDuration8000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass